Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins.
Tumor-associated antigens (TAAs) have been identified mainly to determine cancer prognosis. In the past few years, TAAs have been used in the development of treatment modalities such as tumor vaccination. This review describes an additional application of TAAs: as a target for specific antitumor treatment. Since TAAs are overexpressed on the tumor cell surface, they can be targeted to deliver drugs directly to cancer cells. One such delivery system exploits chimeric proteins. Chimeric proteins are a class of targeted molecules designed to recognize and specifically destroy cells that overexpress specific receptors. These molecules, designed and constructed by gene fusion techniques, comprise both cell-targeting and cell-killing moieties. The authors' laboratory has developed a number of chimeric proteins using gonadotropin-releasing hormone (GnRH) as the targeting moiety. These chimeras recognize a GnRH binding site that is expressed on adenocarcinoma cells. GnRH was fused to a large number of killing moieties, including bacterial and human proapoptotic proteins. All GnRH-based chimeric proteins selectively killed adenocarcinoma cells both in vitro and in vivo. Utilizing chimeric proteins for targeted therapy represents a new and exciting therapeutic modality for the treatment of cancer in humans.
Ben-Yehudah
Ahmi
A
Department of Cellular Biochemistry and Human Genetics, Hebrew University, Hadassah Medical School, Jerusalem, 91120, Israel. ahmi@md.huji.ac.il
Lorberboum-Galski
Haya
H
D000230:Adenocarcinoma / Q000188:drug therapy*; D016503:Drug Delivery Systems; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage*; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*
D011993:Recombinant Fusion Proteins; D007987:Gonadotropin-Releasing Hormone